Literature DB >> 22389391

Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression.

Pantelis A Sarafidis1, Luis M Ruilope.   

Abstract

Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22389391     DOI： 10.1177/1470320312439140

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN： 1470-3203            Impact factor:   1.636


  5 in total

Review 1.  Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.

Authors:  Maria-Eleni Alexandrou; Marieta P Theodorakopoulou; Mehmet Kanbay; Pantelis A Sarafidis
Journal:  J Hum Hypertens       Date:  2022-01-04       Impact factor: 2.877

2.  RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.

Authors:  Rukhsana Gul; Maya Ramdas; Chirag H Mandavia; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-10-27       Impact factor: 2.041

3.  A Pilot Trial on the Effect of Levothyroxine on Proteinuria in Patients With Advanced CKD.

Authors:  Guillermo Navarro Blackaller; Jonathan S Chávez-Iñiguez; Elsa Edith Carreón-Bautista; Francisco Javier González-Torres; Miroslava Villareal-Contreras; José Roberto Barrientos Avalos; Pablo Maggiani Aguilera; Francisco Romo Rosales; Torres Mayorga José Antonio; Juan Alberto Gómez Fregoso; Jorge Isaac Michel Gonzalez; Guillermo García-García
Journal:  Kidney Int Rep       Date:  2020-12-03

Review 4.  SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.

Authors:  Alexia Piperidou; Charalampos Loutradis; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2020-08-10       Impact factor: 3.012

5.  The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury.

Authors:  Frédéric Jaisser; Xiaojuan Tan; Shuangshuang Chi; Jinrong Liu; Ping Wang; Mark Bush; Vincent Benn; Y Fred Yang; Jay Zhang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.